13 / 21
Integrated Efficacy Results:
PFS in Specified Groups According to Platinum Sensitivity
Median PFS ranged from 5.3 to 11.1 months, based on sensitivity to most recent platinum regimen
Median (months)
95% CI
11.1
7.3–12.8
7.4
5.5–Not reached
5.3
1.7–Not reached
Platinum-sensitive (n=79)
Platinum-resistant (n=20)
Platinum-refractory (n=7)
Censored
+
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Months
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Probability of PFS
Platinum-sensitive
At risk (events)
79
(0)
65
(9)
60
(11)
38
(26)
30
(29)
21
(32)
14
(38)
8
(43)
3
(44)
3
(44)
2
(45)
0
(45)
Platinum-resistant 20
(0)
15
(3)
7
(4)
4
(6)
1
(6)
0
(6)
Platinum-refractory 7
(0)
5
(2)
2
(4)
1
(5)
71
(4)
17
(3)
5
(2)
Oza AM et al.
Gynecol Oncol
. 2017;147:267–275